Natsumi Matsumoto

Hatanodai, 1428555, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

Journal: Clinical pharmacokinetics

Published: January 05, 2026

Polymorphisms of FGFR Pathway-related Factors and Capecitabine-induced Hand-foot Syndrome in Japanese Patients With Colorectal Cancer.

Polymorphisms of FGFR Pathway-related Factors and Capecitabine-induced Hand-foot Syndrome in Japanese Patients With Colorectal Cancer.

Journal: Anticancer research

Published: November 20, 2025

Association of IL12RB2, RORC, and class II HLA polymorphisms with severe erythema multiforme of regorafenib in Japanese patients with colorectal cancer.

Association of IL12RB2, RORC, and class II HLA polymorphisms with severe erythema multiforme of regorafenib in Japanese patients with colorectal cancer.

Journal: Cancer chemotherapy and pharmacology

Published: June 11, 2025

ABCC4 polymorphism indirectly reduces systemic exposure to a capecitabine metabolite 5'-deoxy-5-fluorouridine in Japanese subjects.

ABCC4 polymorphism indirectly reduces systemic exposure to a capecitabine metabolite 5'-deoxy-5-fluorouridine in Japanese subjects.

Journal: British journal of clinical pharmacology

Published: September 13, 2024

Association Between ABCC2 -24C>T and Nab-Paclitaxel-induced Peripheral Neuropathy in Japanese Patients With Pancreatic Cancer.

Association Between ABCC2 -24C>T and Nab-Paclitaxel-induced Peripheral Neuropathy in Japanese Patients With Pancreatic Cancer.

Journal: Anticancer research

Published: August 30, 2024

Endoplasmic reticulum transporter OAT2 regulates drug metabolism and interaction.

Endoplasmic reticulum transporter OAT2 regulates drug metabolism and interaction.

Journal: Biochemical pharmacology

Published: January 26, 2024

Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.

Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.

Journal: Cancer chemotherapy and pharmacology

Published: December 04, 2023

A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer.

A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer.

Journal: Cancer chemotherapy and pharmacology

Published: June 05, 2023

Associations of HLA-C01:02 and HLA-B46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancer.

Associations of HLA-C01:02 and HLA-B46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancer.

Journal: Clinical and translational science

Published: May 28, 2023

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study.

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study.

Journal: BMC pulmonary medicine

Published: April 18, 2022

Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.

Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.

Journal: BMC cancer

Published: December 25, 2021

Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.

Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.

Journal: Cancer chemotherapy and pharmacology

Published: April 05, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026